摘要
贫血是慢性肾脏病的常见并发症,严重影响患者的生存寿命和生活质量。罗沙司他是首个用于治疗肾性贫血的口服小分子低氧诱导因子-脯氨酰羟化酶抑制剂,通过促进促红细胞生成素及其受体的表达,抑制低氧诱导因子的泛素化降解,维持低氧诱导因子稳定,改善铁吸收、利用和转运,综合调控红细胞生成,疗效明显,成为治疗肾性贫血的全新途径。近年来,越来越多的证据表明罗沙司他有更多新的应用,其中缺氧保护的机制备受关注。相关动物研究证实,罗沙司他可通过抗氧化应激、抗纤维化等途径发挥对肾脏、肺、心脏、肌肉组织、骨骼组织的保护性作用。同时,相关临床试验证实,罗沙司他可以很好地纠正透析及非透析患者的肾性贫血,并且不受炎症状态影响,在各年龄段人群中均适用。本文就罗沙司他国内外的动物及临床研究进展进行综述,旨在为罗沙司他的应用提供新的依据。
Anemia is a common complication of chronic kidney disease,which seriously affects the life span and quality of life of patients.Roxadustat,which is a oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitors,is first used in the treatment of renal anemia.It promotes the expression of erythropoietin and its receptors,inhibits hypoxia-inducible factor′s ubiquitin degradation,maintains hypoxia-inducible factor′s stability,improves iron absorption,utilization and transportation,comprehensively controls erythropoiesis.Its effect is distinct and it has become a new way to treat renal anemia.Recently,more and more evidences show that Roxadustat has more new applications.Among them,the mechanism of hypoxia protection has attracted much attention.Related animal studies have confirmed that Roxadustat can exert protective effect on kidney,lung,heart,muscle and bone tissues through anti-oxidative stress and anti-fibrosis.Meanwhile,related clinical trials have documented that roxadustat can effectively correct renal anemia in dialysis and non-dialysis patients,and is not affected by the inflammatory state.It is suitable for all age groups.So,this article reviews the progress of animal and clinical research in roxadustat at home and abroad,in order to provide a new basis for its application.
作者
李倩倩
王建刚
刘新宇
LI Qianqian;WANG Jiangang;LIU Xinyu(Clinical Medical School of He′nan University,He′nan Province,Kaifeng 475000,China;Department of Blood Purification,Nanyang Central Hospital,He′nan Province,Nanyang 473000,China)
出处
《中国当代医药》
CAS
2022年第18期36-39,43,共5页
China Modern Medicine
关键词
罗沙司他
肾性贫血
慢性肾脏病
低氧诱导因子
动物研究
临床试验
Roxadustat
Renal anemia
Chronic kidney disease
Hypoxia-inducible factor
Animal study
Clinical trial
